Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Protagonist Therapeutics Inc 7707 GATEWAY BLVD. SUITE 140 NEWARK CA 94560 USA

www.protagonist-inc.com P: 510-474-0170

Description:

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.

Key Statistics

Overview:

Market Capitalization, $K 2,032,292
Enterprise Value, $K 1,845,562
Shares Outstanding, K 58,652
Annual Sales, $ 60,000 K
Annual Net Income, $ -78,960 K
Last Quarter Sales, $ 254,950 K
Last Quarter Net Income, $ 207,340 K
EBIT, $ 88,680 K
EBITDA, $ 87,420 K
60-Month Beta 2.12
% of Insider Shareholders 5.40%
% of Institutional Shareholders 98.63%
Float, K 55,485
% Float 94.60%
Short Volume Ratio 0.25

Growth:

1-Year Return 28.01%
3-Year Return -25.26%
5-Year Return 169.86%
5-Year Revenue Growth 93.99%
5-Year Earnings Growth 20.11%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 3.26 on 05/07/24
Next Earnings Date 08/01/24
Earnings Per Share ttm 2.44
EPS Growth vs. Prev Qtr 640.91%
EPS Growth vs. Prev Year 586.57%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

PTGX Ratios

Ratio
Price/Earnings ttm 13.07
Price/Earnings forward 13.98
Price/Earnings to Growth N/A
Return-on-Equity % 43.42%
Return-on-Assets % 39.59%
Profit Margin % -131.60%
Debt/Equity 0.00
Price/Sales 31.16
Price/Cash Flow N/A
Price/Book 3.34
Book Value/Share 9.56
Interest Coverage -1.36
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar